| Authors | Paul S Giacomini, Ayal Rozenberg, Imke Metz, David Araujo, Nathalie Arbour, Amit Bar-Or, Maraviroc in Multiple Sclerosis–Associated PML–IRIS (MIMSAPI) Group |
| Journal | The New England journal of medicine
(N Engl J Med)
Vol. 370
Issue 5
Pg. 486-8
(Jan 30 2014)
ISSN: 1533-4406 [Electronic] United States |
| PMID | 24476450
(Publication Type: Case Reports, Letter)
|
| Chemical References |
- Antibodies, Monoclonal, Humanized
- CCR5 Receptor Antagonists
- Cyclohexanes
- Natalizumab
- Receptors, CCR5
- Triazoles
- Maraviroc
|
| Topics |
- Adult
- Antibodies, Monoclonal, Humanized
(adverse effects, therapeutic use)
- CCR5 Receptor Antagonists
- Cyclohexanes
(therapeutic use)
- Female
- Humans
- Immune Reconstitution Inflammatory Syndrome
(drug therapy, virology)
- Immunocompromised Host
- JC Virus
- Leukoencephalopathy, Progressive Multifocal
(drug therapy, etiology)
- Maraviroc
- Multiple Sclerosis, Relapsing-Remitting
(complications, drug therapy)
- Natalizumab
- Receptors, CCR5
(immunology)
- Triazoles
(therapeutic use)
- Viral Load
|
